SynthesisJournal of psychopharmacology (Oxford, England)2025
Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: A systematic review and meta-analysis of clinical trial data.
Synthesis in Journal of psychopharmacology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: A systematic review and meta-analysis of clinical trial data.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntipsychotic-induced weight gain (AIWG) is a major concern in psychiatry, where there is a mortality gap between those with mental illness, particularly schizophrenia, and the general population. One development proposed is using centrally-acting opioid receptor antagonists (CORAs) such as naltrexone and samidorphan.
objectiveThe systematic review and meta-analysis evaluated the available human clinical trial data on the effect of CORA on AIWG. METHODOLOGY: Four online databases (MEDLINE, EMBASE, PsycINFO, and Cochrane) were searched for randomized-controlled trials (RCTs) on the topic. The primary outcome was change in bodyweight. Secondary anthropometric outcomes included percentage bodyweight change, BMI change, and absolute risk of weight gain. Meta-analysis was conducted on primary outcome.
resultsNine RCT articles (samidorphan = 6, naltrexone = 3) and two extension studies from RCTs (both samidorphan) were identified. Meta-analysis of four RCTs (
conclusionCORA, specifically samidorphan, was effective at reducing weight gain in individuals prescribed olanzapine. The small effect sizes and discrepancy between samidorphan and naltrexone suggest effects may be timing dependent, not a class effect, or dependent on the antipsychotic combination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.